Literature DB >> 22245505

Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study.

Chiara Giordanino1, Simone Ceretto, Simona Bo, Antonina Smedile, Alessia Ciancio, Elisabetta Bugianesi, Rinaldo Pellicano, Sharmila Fagoonee, Elisabetta Versino, Giuseppe Costa, Daniele Arese, Marco Sacco, Mario Rizzetto, Giorgio Saracco.   

Abstract

BACKGROUND: The long-term outcome in patients with chronic hepatitis C and type 2 diabetes mellitus treated with interferon and ribavirin is unclear. We compared incidence of liver-related events and mortality rates between hepatitis C virus-positive patients with or without diabetes mellitus, and the incidence of diabetes-related events between diabetic patients with and without hepatitis C.
METHODS: Retrospective study of 309 patients with chronic hepatitis C. Incidence of liver-related events, diabetes-related events and mortality rates were assessed over a mean follow-up of 11.02±4.9 years.
RESULTS: 50 (16%) chronic hepatitis C patients had diabetes mellitus. Diabetics showed a higher number of diabetes- and liver-related events than non-diabetics (10% vs 1.5%, p=0.006; 18% vs 5.7%, p=0.007, respectively) with a mortality of 14% vs 1.5% (p=0.0003). Baseline cirrhosis (p=0.002) and non-sustained virological response (p=0.01) were independent risk factors for liver events; diabetes mellitus (p=0.01) and hypertension (p=0.0017) were independent factors for diabetes-related events.
CONCLUSIONS: In patients with chronic hepatitis C, comorbidity with diabetes mellitus was associated with a higher mortality rate and incidence of liver/diabetes-related events. Independent risk factors for liver-related events were the non-response to antiviral therapy and cirrhosis at baseline.
Copyright © 2011 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22245505     DOI: 10.1016/j.dld.2011.12.003

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  7 in total

1.  Association between diabetes mellitus and cirrhosis mortality: the Singapore Chinese Health Study.

Authors:  George Boon-Bee Goh; An Pan; Wan-Cheng Chow; Jian-Min Yuan; Woon-Puay Koh
Journal:  Liver Int       Date:  2016-09-16       Impact factor: 5.828

2.  Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study.

Authors:  Qing-Lei Zeng; Guo-Hua Feng; Ji-Yuan Zhang; Yan Chen; Bin Yang; Hui-Huang Huang; Xue-Xiu Zhang; Zheng Zhang; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 3.  Metabolic factors and chronic hepatitis C: a complex interplay.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Maria Giovanna Minissale; Teresa Li Vigni; Simona Attardo; Emanuele Orlando; Salvatore Petta
Journal:  Biomed Res Int       Date:  2013-07-17       Impact factor: 3.411

4.  Network-based study reveals potential infection pathways of hepatitis-C leading to various diseases.

Authors:  Anirban Mukhopadhyay; Ujjwal Maulik
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

5.  The spectrum of cutaneous infection in diabetic patients with hepatitis C virus infection: a single-center study from egypt.

Authors:  Mohamed A El-Khalawany; Ali M Mahmoud
Journal:  Indian J Dermatol       Date:  2014-05       Impact factor: 1.494

6.  Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study.

Authors:  Qing-Lei Zeng; Bing Li; Xue-Xiu Zhang; Yan Chen; Yan-Ling Fu; Jun Lv; Yan-Min Liu; Zu-Jiang Yu
Journal:  Gut Liver       Date:  2016-11-15       Impact factor: 4.519

7.  Bayesian network modelling study to identify factors influencing the risk of cardiovascular disease in Canadian adults with hepatitis C virus infection.

Authors:  Alaa Badawi; Giancarlo Di Giuseppe; Alind Gupta; Abbey Poirier; Paul Arora
Journal:  BMJ Open       Date:  2020-05-05       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.